

In The Claims:

The claims are amended as follows:

1-49. (Cancelled)

50. (Previously Presented) A method of determining a treatment regimen for a subject, comprising:

selecting said subject on the basis of a diagnosis of congestive heart failure, acute coronary syndrome or acute myocardial infarction;

performing an assay to specifically detect a natriuretic peptide in a sample obtained from said subject, wherein said natriuretic peptide is BNP₇₇₋₁₀₈; and

determining a treatment regimen based in part on the presence or amount of said natriuretic peptide, wherein said regimen includes one or more inhibitors of prolyl-specific DPP.

51. (Previously Presented) A method according to claim 50, wherein the inhibitor(s) of prolyl-specific DPP comprise a dipeptide analogue comprising an aza, azetidine, boronate, hydroxylamine, or phosphonate moiety.

52. (Previously Presented) A method according to claim 50, wherein the inhibitor(s) of prolyl-specific DPP comprise an antibody or fragment thereof.

53. (Previously Presented) A method according to claim 50, wherein said regimen further comprises one or more additional molecules selected from the group consisting of inhibitors of neutral endopeptidase and natriuretic peptides.

54. (Previously Presented) The method of claim 50, wherein said performing step comprises:

forming a complex between said natriuretic peptide and at least one antibody, wherein said antibody comprises a detectable label; and

detecting said complex.